Foundation Care, local specialty pharmacy, is selected to be one of four to provide cystic fibrosis patients with the new drug Cayston® (aztreonam for inhalation solution) nationwide.

February 23, 2010 – Foundation Care Pharmacy, located in Earth City, MO, was selected by Gilead Sciences, Inc. to be one of four specialty pharmacies nationwide to provide cystic fibrosis patients with the new drug Cayston® (aztreonam for inhalation solution). Cayston is the first new inhaled antibiotic approved for use in cystic fibrosis in more than a decade.

On February 22, 2010, Gilead was granted marketing approval for Cayston as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa). Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second (FEV1) of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia. Cystic Fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide).

Cayston is administered at a dose of 75mg three times daily over a 28 day period and is delivered via the Altera® Nebulizer System based on eFlow Technology (Pari Pharma GmbH). Altera is a drug specific nebulizer cleared by the FDA only to deliver Cayston. Altera allows patients to administer Cayston in 2 to 3 minutes, a fraction of the time required for other inhaled antibiotics!

Foundation Care opened its doors in 2004 as a full service retail pharmacy with a specialty in treating Cystic Fibrosis. Since then, their pharmacists and staff have become extremely knowledgeable in the treatment of CF and have years of experience with inhaled respiratory medications and eFlow technology. Also, their relationships with caregivers, physicians, and insurance providers across the nation ensure that each patient receives the expertise and guidance needed in today’s complex healthcare world.

Over the years, Foundation Care has constantly strived to find new ways to make a patient’s treatment easier and more affordable. “This partnership with Gilead is just another step toward improving the lives and offering treatment alternatives for our patients with Cystic Fibrosis,” Daniel Blakeley, RPh, Owner and Chief Executive Officer of Foundation Care.

About Foundation Care

As a full service pharmacy, Foundation Care continues to provide the most up-to-date medications while working to make our patients treatment easier and more affordable. Located in the Saint Louis, MO area, Foundation Care serves patients locally and nationwide. For additional information, visit www.FoundCare.com or call Foundation Care at (314) 291-1122 or toll‐free at (877) 291-1122.